epidermal growth factor
Sign in to saveAlso known as EGF, pro-epidermal growth factor, beta-urogastrone
mammalian protein found in Homo sapiens
Protein · UniProt
Pro-epidermal growth factor
- Gene
- EGF
- Organism
- Homo sapiens (Human)
- Length
- 1,207 aa
- Molecular mass
- 133,994 Da
- Evidence
- 1: Evidence at protein level
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941)
3D-structureAlternative splicingDirect protein sequencingDisease variantDisulfide bondEGF-like domainGlycoproteinGrowth factor
View on UniProt →
Swiss-Prot (reviewed) · via UniProt
Research
104,339 papers- [Progress in human epidermal growth factor research].Sheng wu gong cheng xue bao = Chinese journal of biotechnology · 2020
- Epidermal growth factor.In vitro cellular & developmental biology : journal of the Tissue Culture Association · 1987
- Epidermal growth factor and related molecules.Lancet (London, England) · 1989
- The epidermal growth factor (EGF).Cancer · 1983
- Epidermal growth factor: biology and mechanism of action.Birth defects original article series · 1980
via PubMed
Clinical Trials
1,022 registered- PHASE2TERMINATEDWindow of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRUniversity of Wisconsin, Madison · NCT02720185
- COMPLETEDTNFα and MFG-E8: Novel Biomarkers to Predict Implantation FailureEastern Virginia Medical School · NCT02386384
- NACOMPLETEDTetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for CancerAlliance for Clinical Trials in Oncology · NCT00091247
- NAUNKNOWNBlood Detection of EGFR Mutation For Iressa TreatmentPeking University Cancer Hospital & Institute · NCT02282267
- PHASE2COMPLETEDIressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentAstraZeneca · NCT01530334
- PHASE1COMPLETEDEffect of Panitumumab on the Pharmacokinetics of IrinotecanAmgen · NCT00563316